• 1. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966

Recent Advances in the Application of 2-Fluoro-6-(3-thienyl)pyridine-3-boronic acid (CAS: 2225177-72-8) in Chemical Biology and Pharmaceutical Research

2-Fluoro-6-(3-thienyl)pyridine-3-boronic acid (CAS: 2225177-72-8) has emerged as a versatile building block in medicinal chemistry and chemical biology, particularly in the development of novel therapeutics and diagnostic tools. This boronic acid derivative has garnered significant attention due to its unique structural features, which enable its participation in Suzuki-Miyaura cross-coupling reactions, a cornerstone of modern drug discovery. Recent studies have highlighted its potential in targeting various disease pathways, including cancer and infectious diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 2-Fluoro-6-(3-thienyl)pyridine-3-boronic acid in the synthesis of kinase inhibitors. The researchers utilized this compound as a key intermediate to develop a series of pyridine-based inhibitors targeting the PI3K/AKT/mTOR pathway, which is frequently dysregulated in cancer. The study reported that derivatives incorporating this boronic acid exhibited enhanced selectivity and potency compared to traditional inhibitors, with IC50 values in the low nanomolar range.

In the field of infectious disease, a recent publication in Bioorganic & Medicinal Chemistry Letters (2024) explored the use of 2-Fluoro-6-(3-thienyl)pyridine-3-boronic acid in the development of antiviral agents. The compound served as a crucial scaffold for designing inhibitors of viral proteases, particularly those associated with SARS-CoV-2 and influenza. The study's molecular docking simulations revealed that the fluorine atom and thienyl group in this boronic acid contribute to optimal binding interactions with the active sites of these viral enzymes.

Beyond therapeutic applications, this compound has shown promise in diagnostic imaging. A 2024 study in Chemical Communications detailed its use in the synthesis of PET (positron emission tomography) radiotracers. The boronic acid moiety allowed for efficient radiolabeling with fluorine-18, while the pyridine-thiophene core provided favorable pharmacokinetic properties for tumor imaging. Preliminary in vivo studies demonstrated excellent tumor-to-background ratios in xenograft models, suggesting potential for clinical translation.

The synthetic versatility of 2-Fluoro-6-(3-thienyl)pyridine-3-boronic acid has also been exploited in materials science applications. Researchers have recently incorporated this compound into conjugated polymers for organic electronic devices, taking advantage of its electron-deficient pyridine ring and the electron-rich thiophene unit. These materials have shown potential in biosensing applications, particularly for the detection of biologically relevant analytes such as glucose and dopamine.

Despite these advances, challenges remain in the large-scale production and purification of 2-Fluoro-6-(3-thienyl)pyridine-3-boronic acid. Recent process chemistry studies have focused on optimizing its synthesis to improve yield and purity while reducing environmental impact. A 2023 report in Organic Process Research & Development presented a novel catalytic system that achieves >90% yield with excellent regioselectivity, addressing previous limitations in its manufacturing.

Looking forward, the unique properties of 2-Fluoro-6-(3-thienyl)pyridine-3-boronic acid position it as a valuable tool in drug discovery and chemical biology. Ongoing research is exploring its potential in targeted protein degradation (PROTACs), antibody-drug conjugates, and as a warhead in covalent inhibitors. As synthetic methodologies continue to advance, we anticipate seeing broader applications of this compound across multiple therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)